Paper Details

  1. Home
  2. Paper Details

OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.

Author: AuerbachStephen, FowlerClare J, GinsbergDavid, HaleDouglass, KowalskiJonathan W, PatelVaishali D, RadziszewskiPiotr, RechbergerTomasz, ThompsonCatherine, ZhouJihao

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of onabotulinumtoxinA in patients with idiopathic overactive bladder (OAB) and urgency urinary incontinence (UUI) refractory to oral antimuscarinics. Treatment with doses of 100 U or higher resulted in statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL) compared to placebo, sustained for up to 36 weeks.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Patients with urgency urinary incontinence (UUI) due to overactive bladder (OAB) refractory to oral antimuscarinics have limited therapeutic options. OnabotulinumtoxinA appears to be an effective new treatment. OBJECTIVE: Assess disease-specific quality-of-life outcomes and general heal...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2012.03.005

データ提供：米国国立医学図書館（NLM）

OnabotulinumtoxinA: A New Oasis in the Desert of Urinary Incontinence

In the vast and often uncomfortable desert of urinary incontinence, we seek treatments that provide relief and improve quality of life. This study explores the use of onabotulinumtoxinA, a medication commonly known as Botox, as a treatment for urinary incontinence due to overactive bladder. It's like finding a cool spring in the desert, offering a much-needed respite from the discomfort and inconvenience of urinary incontinence.

Botox for Urinary Incontinence: A New Oasis

The study, a double-blind randomized controlled trial, investigated the effectiveness of onabotulinumtoxinA in patients with overactive bladder who were not adequately responding to conventional medications. The researchers found that onabotulinumtoxinA significantly improved urinary incontinence symptoms and overall quality of life in these patients. This discovery is significant because it offers a new treatment option for patients who have not found relief with other methods, like finding a hidden oasis in the vast desert of urinary incontinence.

Navigating the Desert of Bladder Control

This research provides valuable insights into the potential of onabotulinumtoxinA for treating urinary incontinence. It's a promising development, offering a new path to explore in the desert of bladder control. Further research is needed to refine the treatment protocols and to determine its long-term efficacy and safety.

Dr.Camel's Conclusion

This study reveals the potential of onabotulinumtoxinA for providing relief from the discomfort and inconvenience of urinary incontinence, offering a refreshing oasis in the desert of bladder control. It's a testament to the ongoing search for innovative treatments, ensuring that those seeking relief have access to a wider range of options.

Date :
  1. Date Completed 2012-12-10
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22464310

DOI: Digital Object Identifier

10.1016/j.eururo.2012.03.005

Related Literature

Article Analysis
・Effective treatment of urinary incontinence
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.